Brief: NetraMark Holdings Signs Contract With AlgoTx To Enhance Clinical Trial Design For ATX01
28/07/2025 14:09
July 28 (Reuters) - NetraMark Holdings Inc AIAI.CD: NETRAMARK SIGNS CONTRACT WITH ALGOTX TO ENHANCE CLINICAL TRIAL DESIGN FOR ATX01 Source text: ID:nGNX8nW2mj Further company coverage: AIAI.CD ((Reuters.Briefs@thomsonreuters.com;))
Recent news on NetraMark Holdings
See all newsBrief: Netramark Announces Uplisting To Toronto Stock Exchange
Brief: Netramark Signs Four New Contracts With A Leading Global Pharmaceutical Company To Enhance Clinical Trial Insights
Brief: Asklepion Pharmaceuticals Signs Contract To Utilize Netramark Technology In Phase III Pediatric Cardiac Study
Brief: NetraMark Holdings Signs Contract With AlgoTx To Enhance Clinical Trial Design For ATX01
Brief: Netramark And Worldwide Clinical Trials Announce Agreement To Transform Clinical Trial Design With Ai-Powered Precision